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ABSTRACT 
Solid dispersions can be a successful way to enhance the bioavailability of poorly soluble 
drugs. Here 60 solid dispersion formulations were produced using ten chemically diverse, 
neutral, poorly soluble drugs, three commonly used polymers, and two manufacturing 
techniques, spray drying and melt extrusion. Each formulation underwent a six-month stability 
study at accelerated conditions, 40 °C and 75% relative humidity (RH). Significant differences 
in times to crystallisation (onset of crystallisation) were observed between both the different 
polymers and the two processing methods. Stability from zero days to over one year was 
observed. The extensive experimental dataset obtained from this stability study was used to 
build multiple linear regression models to correlate physicochemical properties of the active 
pharmaceutical ingredients (API) with the stability data. The purpose of these models is to 
indicate which combination of processing method and polymer carrier is most likely to give a 
stable solid dispersion. Six quantitative mathematical multiple linear regression-based models 
were produced based on selection of the most influential independent physical and chemical 
parameters from a set of 33 possible factors, one model for each combination of polymer and 
processing method, with good predictability of stability. Three general rules are proposed from 
these models for the formulation development of suitably stable solid dispersions. Namely, 
increased stability is correlated with increased glass transition temperature (Tg) of solid 
dispersions, as well as decreased number of H-bond donors and increased molecular flexibility 
(such as rotatable bonds and ring count) of the drug molecule. 
 
Keywords: solid dispersion, stability, multiple linear regression model, hot melt extrusion, 
spray-drying, amorphous  
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INTRODUCTION 
Poor water solubility (and hence bioavailability) of drugs in development is an ongoing and 
challenging problem, as up to 75% of new chemical entities (NCE) in small-molecule drug 
pipelines are poorly water soluble 1,2. Poor solubility increases the risk of delays and failure in 
the development of a NCE 3. There are several possible routes that can be taken in order to 
enhance the solubility and bioavailability of drugs through formulation. These include particle 
size reduction, polymorph optimisation, lipid formulations, and solid dispersions, as reviewed 
by Williams et al. 4.  
Solid dispersions can significantly increase the effective solubility and thus bioavailability of 
poorly soluble drugs. This can be accomplished by two strategies; particle size reduction so 
that the drug is dispersed as tiny particles, or molecular dispersion in a soluble polymeric 
carrier. The drug is also, if in particulate form, usually dispersed in an amorphous form, which 
gives increased solubility compared to the crystalline form 5–9. As the amorphous form is 
generally unstable, it is likely to convert to the more stable crystalline form, which in turn 
reduces solubility. Other processes and factors can also contribute to instability within a solid 
dispersion, inclusive of phase segregation leading to regions with different compositions, 
chemical degradation of the API leading to products that may alter crystallisation tendencies 
and water uptake by the matrix polymer that can affect drug and polymer mobility and hence 
stability10. Physical stability of solid dispersions is therefore the most significant obstacle that 
must be overcome in their development. Choosing an appropriate polymer and processing 
method is pivotal in producing a successful product as it will greatly affect the stability of the 
solid dispersions. The most commonly used manufacturing methods are spray-drying and hot 
melt extrusion (HME) as these are relatively easy to scale up and produce well mixed 
dispersions 11,12. The chosen polymer carrier stabilises both the drug in the solid form and in 
the solid-solution, retarding crystallisation 7,13. Solid dispersions have been extensively studied 
in this context (reviewed by Leuner and Dressman 14). Solid dispersions have been used 
successfully to enhance the bioavailability of drugs in several marketed products as 
summarised in Table 1. 
TABLE 1. Summary of marketed solid dispersions in oral dosage forms, including the brand name, the APIs they contain and 
the polymer carriers used 7,15,16. The following abbreviations are used: PEG - polyethylene glycol, PVP – polyvinylpyrrolidone, 
HPMC - hydroxypropyl methylcellulose, HPMCAS - hydroxypropyl methylcellulose acetate succinate, HPC - hydroxypropyl 
cellulose. 
Brand name API Polymer carrier  
Adalat SL Nifedipine PEG 
Afeditab CR Nifedipine Poloxamer-PVP 
Certican Everolimus HPMC 
Cesamet Nabilone PVP 
Crestor Rovustatin HPMC 
Envarsus Tacrolimus HPMC 
Fenoglide Fenofibrate PEG 
Gris-PEG Griseofulvin PEG 
Incivo Telaprevir HPMCAS 
Intelence Etravirine HPMC 
Isoptin SR-E Verapamil HPC/HPMC 
Kaletra Lopinavir/Ritonavir PVP-VA 
Kalydeco Ivacaftor HPMCAS 
4 
 
Lopinavir/Ritonavir Mylan Lopinavir /Ritonavir HPMCAS 
Modigraf Tacrolimus HPMC 
Nivadil Nivaldipine HPMC 
Noxafil Posaconazole HPMCAS 
Orkambi Lumacaftor / Ivacaftor HPMCAS 
Prograf Tacrolimus HPMC 
Rezulin Troglitazone HPMC 
Sporanox  Itraconazole HPMC 
Viekirax Ombitasvir/Paritaprevir/Ritonavir PVP-VA 
Votubia Everolimus HPMC 
Zelboraf Vemurafenib HPMCAS 
 
Choosing the most appropriate formulation route for a new drug is to a large extent still based 
on formulator know-how and experimental screening assays. Properties of the Active 
Pharmaceutical Ingredient (API) are often not considered, but rather in-house knowledge and 
availability of equipment steer the process 17,18. We propose that a knowledge-based 
computational tool that could predict the best formulation strategy would greatly improve this 
process. Indeed there are some support tools available that can be used to facilitate this process 
such as guidance maps, high through-put screening, and statistical models, as we recently 
reviewed 19. Using a support tool in the formulation development can shorten the development 
process, limiting the number of experiments that need to be carried out by indicating which 
formulation route is appropriate for a specific API and there remains a significant need in this 
area. 
As the choice of polymer carrier and processing method are vital to the consequent stability of 
a solid dispersion, the use of a knowledge-based support tool in the formulation development 
is very beneficial. Currently, although some effort has been put into building such tools, their 
availability remains quite limited 18,20. Several models have been built to predict the glass-
forming ability of APIs and some predict the stability of the amorphous form of APIs. These 
are intended to give an indication of whether a dosage form containing the API in amorphous 
form is a viable formulation choice 21–26. Recently molecular dynamics (MD) simulations have 
been used to predict Tg, investigate interactions between drug and polymer in solid dispersions, 
and the effect of water in the system 27. Historically the Flory-Huggins equation or Hansen 
solubility parameters have also been used theoretically to analyse interactions and miscibility 
and provide an indication of likely stability. The advancement of a computational tool that can 
compare several solid dispersion formulations and predict their stability has not yet been 
achieved.  
Many researchers have focused on the stability of solid dispersions in their studies, in particular 
which factors inhibit crystallisation 28–31. With better knowledge of which factors are important 
for stabilisation, such as drug-polymer interaction, polymer Tg and hygroscopicity, formulation 
development of solid dispersions could be improved. This in turn could ease the path of such 
new formulations to the market. However, although many drugs and polymers have been 
researched, the number of APIs in such studies is often very limited. This, and the fact that 
there is little agreement in results between different studies, makes it difficult to draw any 
general conclusions, as has been noted before 32. Therefore, the aim of the present study is to 
produce and test the stability of a large number (60) of solid dispersions using chemically 
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diverse APIs (10), commonly used polymers (3) and well-known processing methods, spray 
drying and melt-extrusion. This approach should yield more general conclusions about 
important factors for solid dispersions physical stability. The dataset was then used to build a 
statistical predictive model that should be able to highlight which physicochemical properties 
of the APIs are correlated with formulation stability. The models could then be used to facilitate 
formulation development of solid dispersions by indicating which combination of polymer and 
processing method is most suitable for a new drug.  
 
MATERIALS AND METHODS 
Ten poorly soluble, neutral (pKaAcid> 8.5 and pKaBasic< 4.5), chemically diverse APIs (purity 
99% unless otherwise indicated): nifedipine (1), felodipine (2), itraconazole (3), probucol (4), 
ritonavir (5), fenofibrate (6), celecoxib (7), estradiol (8), orlistat (9), and aprepitant (10) (purity 
98%), see Figure 2, were purchased from Seqouia Research Products Ltd. Three polymers were 
generous gifts from their commercial suppliers: Soluplus (PCL-PVAc-PEG, SOL) and 
Kollidon VA64 (PVP-VA) from BASF, AquaSolve (HPMCAS-HG)) from Ashland (Figure 
1). The molecular weight distribution of the three polymers was as follows, 45.000-70.000 Da 
for PVP-VA, 55.000-90.000 Da for HPMCAS and 90.000-140.000 Da for SOL. Binary solid 
dispersions were made for each combination of polymer and drug. Each combination was 
produced twice, once using hot melt extrusion (HME) and once by spray-drying. Each 
formulation was then subjected to a stability test and characterised at each time point. The 
following abbreviations of formulations are used below, numbers one to ten for the APIs as 
listed above (Figure 2). For the polymers S, P and H for Soluplus, PVP-VA, and HPMCAS, 
respectively. Hot melt extrusion (h) and spray-drying (s). Thus e.g. spray-dried ritonavir – 
PVP-VA is abbreviated 5Ps.  
 
Figure 1 The chemical structure of PVP-VA (P), HPMCAS (H), and SOL (S).  
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Figure 2 Chemical structure of the ten APIs used in this study.  
 
HOT MELT EXTRUSION 
A HAAKE minilab II micro compounder (Thermo Fisher Scientific) was used for the 
production of the HME solid dispersions. All formulations were made with 10% w/w drug 
loading in polymer. In order to keep the number of variables as low as possible all solid 
dispersions were produced using the same method and no optimisation was performed for any 
formulation. API and polymer were weighed and mixed in a scintillation vial. Once the minilab 
had reached the set temperature of 160 °C, the mixture was fed into the hopper. The twin screws 
were co-rotated at 50 r.p.m. and the mixture was circulated for 15 min before being extruded. 
The same method was used for all formulations except those containing orlistat, which was not 
circulated but extruded immediately because of its low melting point (44 °C). The processing 
temperature of 160 °C was selected as an optimal value suitable for the processing of all the 
selected materials and one that did not cause degradation of the materials during the exposure 
to this temperature. This processing temperature of is above the Tg of all three polymers. 
Therefore, for the three APIs with a melting points above 160 °C as long as they are miscible 
in the polymer they should dissolve in the polymer and be fully amorphisised and mixed in the 
solid dispersion. The success of this approach, or not, would be apparent from studies of the 
melt extruded mixtures. These did not result in markedly less stabile formulations than those 
APIs with lower mp.  Once extruded, the formulation was placed into amber HPLC vials and 
stored at 5 °C / 0% RH until the start of the stability study. 
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SPRAY-DRYING 
As with the HME formulations, to keep the number of variables at a minimum, the same 
method was used to produce all formulations. All were produced using the same solvent, except 
itraconazole that was not soluble in methanol and was therefore dissolved in dichloromethane. 
Spray-drying was performed using a Büchi B290 instrument. Each drug-polymer mixture was 
dissolved in methanol at 10% w/v and spray-dried within half an hour. Once the mixture was 
fully dissolved in the solvent the solution was sprayed through the nozzle using an inlet 
temperature of around 80 °C to maintain an outlet temperature of 50 °C. The produced 
formulation was then collected and weighed before being placed in amber HPLC vials and 
stored at 5 °C / 0% RH until the stability study was started.  
STABILITY 
A six-month stability study was conducted on all produced solid dispersions at accelerated 
conditions, 40 °C / 75% RH, in accordance with ICH guidelines 33. The samples were kept 
glass vials, open containers and conditions were monitored using a Testo 174H temperature 
and humidity logger. The amorphicity of the formulations was confirmed at the start of the 
stability study. Subsequently the solid dispersions were analysed at 12 h, 7 d, 1 month, 2 
months, 4 months and 6 months. For those solid dispersions that were still amorphous after 6 
months, a 1-year time point was added. At each of these time points the samples were examined 
for signs of crystallinity using polarised light microscopy (PLM) as a sensitive method to detect 
onset of crystallisation. Any formulations with signs of crystallinity by PLM were then further 
characterised using differential scanning calorimetry (DSC) and X-ray powder diffraction 
(XRPD). Before analysing the samples at each time point the formulation was ground in a 
mortar, if necessary, producing small glass-like pieces appropriate for characterisation with 
PLM, DSC, and XRPD. 
POLARISED LIGHT MICROSCOPY 
An Olympus BX51 optical microscope fitted with polarising filters and equipped with an 
Olympus DP71 camera was used visually to check for presence of any crystalline material. A 
small amount of powder (spray-dried) or ground glass (HME) was placed on a microscope 
slide with a glass cover slip. The samples were examined using both cross-polarised and non-
polarised light. Images of identical frames were recorded for each sample under both polarised 
and non-polarised light. Cell˄F imaging system from Olympus was used to acquire images of 
the samples. 
DIFFERENTIAL SCANNING CALORIMETRY 
A Q2000 (TA instruments) was used for the DSC measurements of all samples, using Tzero 
pans (TA instruments) and pierced lids. The instrument was calibrated against indium. 
Approximately 5 mg of sample was weighed into each pan. Each sample was run in duplicate. 
All solid dispersions, except orlistat, were run as a cycle where the first ramp was used to 
remove water and solvent from the formulation. The second time the sample was ramped up to 
20 °C above the melting point of the drug. Both up and down ramps were performed at 10 
°C/min. As orlistat has a melting point of 44 °C it was not feasible to go above 100°C in order 
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to remove water before running the sample as this might have affected the solid dispersion. It 
was therefore run as a single ramp. The results were analysed using the TA Universal Analysis 
programme to determine Tg and melting points (mp). 
X-RAY POWDER DIFFRACTION 
A Bruker D8 Advance instrument using a Cu Kα1 radiation source and equipped with an 
incident beam monochromator was used for the XRPD measurements. The instrument was 
calibrated against corundum. All samples were analysed with spinning at a current of 40 mA 
and a voltage of 40 kV using standard scanning parameters, i.e. from 2 to 40° (2 θ) using a step 
size of 0.02° and a time per step of 1 s. A zero-background holder was used for the 
measurements of samples of approximately 3-5 mg. The program DIFFRAC.SUIT EVA from 
Bruker was used to analyse and plot the data, no adjustments were done to the baseline during 
plotting. 
PHYSICOCHEMICAL PROPERTIES OF APIS 
The program Instant JChem from ChemAxon was used to calculate and predict 
physicochemical properties of the APIs. These were based on the molecular structure of each 
API. Furthermore information on the melting point (mp) of each drug was obtained from 
Chemspider, these did not differ significantly from measured mp 34. The following parameters 
were included in the modelling process: molecular weight (MW), lipophilicity (ClogP) 
determined using the ChemAxon method, strongest basic pKa (b.pKa), topological polar 
surface area (tPSA), number of atoms (nAtom), number of bonds (nBond), number of chiral 
atoms (nChir), number of H-bond acceptors (HBA), number of H-bond donors (HBD), number 
of rings (nRing), number of nonterminal rotatable bonds (nRot), number of aliphatic atoms 
(nAliph), number of aromatic atoms (nAr), water accessible surface area (ASA), average 
polarizability (avPol), hydrophilicity-lipophilicity balance (HLB), intrinsic water solubility in 
log10 of molar solubility (logS0), molecular polarizability (molPol), van der Waals surface area 
(vdW-SA), melting point (mp), number of aliphatic rings (nAliphRing), number of aromatic 
rings (nAr), number of carbon atoms (nC), number of fluorine (nF) atoms, number of nitrogen 
atoms (nN), number of oxygen atoms (nO), number of sulphur atoms (nS), number of chlorine 
atoms (nCl), number of heteroatoms (atoms other than carbon and hydrogen; nHet), number of 
sp3 carbon atoms, number of sp2 carbon atoms, measured Tg (Tg,meas) and predicted Tg (Tg,pred) 
in oC, where the Fox equation was used to calculate the expected Tg of the solid dispersion. 
The predicted value was also used as a Tg,meas, in those instances where a Tg could not be 
measured. The physicochemical properties used and their values are listed in Table 2.  
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TABLE 2 Calculated and predicted parameters used in the building of the MLR models. 
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nAliph 19 19 21 23 28 13 9 14 35 20 
nAliphRing 1 1 2 0 0 0 0 3 1 1 
nAr 6 6 28 12 22 12 17 6 0 17 
nArRing 1 1 5 2 4 2 3 1 0 3 
ASA (Å2) 533 583 976 874 981 642 602 392 985 679 
nAtom 43 44 87 83 98 46 40 44 88 58 
avPol (Å3) 33 37 74 62 76 38 35 32 61 44 
nBond 44 45 93 84 101 47 42 47 88 61 
nChir 0 1 3 0 4 0 0 5 4 3 
HBA 5 3 9 2 6 3 3 2 3 6 
HBD 1 1 0 2 4 0 1 2 1 2 
nHet 8 7 14 4 13 5 9 2 6 14 
HLB 16 11 5 2 4 4 4 2 3 16 
logS0 (M) -3 -4 -9 -11 -8 -6 -6 -4 -11 -6 
logP 1.82 3.44 7.31 10.57 5.22 5.28 4.01 3.75 8.11 4.52 
MW 346.3 384.3 705.6 519.8 721.0 360.8 381.4 272.4 495.8 534.4 
molPol (Å3) 33 37 71 61 75 38 36 31 56 43 
mp (°C) 173 145 166 125 121 81 158 152 44 255 
nC 17 18 35 31 37 20 17 18 29 23 
nCl 0 2 2 0 0 1 0 0 0 0 
nF 0 0 0 0 0 0 3 0 0 7 
nN 2 1 8 0 6 0 3 0 1 4 
nO 6 4 4 2 5 4 2 2 5 3 
nS 0 0 0 2 2 0 1 0 0 0 
nRing 2 2 7 2 4 2 3 4 1 4 
nRot 6 6 11 8 18 7 4 0 23 8 
sp2 12 12 22 12 21 14 15 6 3 14 
sp3 5 6 13 19 16 6 2 12 26 9 
b.pKa -6.63 -6.64 3.92 -5.08 2.84 -4.93 0.08 -0.88 -1.44 3.74 
tPSA (Å2) 107.8 64.6 100.8 40.5 145.8 52.6 78.0 40.5 81.7 75.2 
vdW-SA (Å2) 466 493 965 916 1,065 533 484 437 925 656 
Sh Tg meas (°C) 70.2 68.2 68.5 68.9 66.6 56.1 72.7 64.2 NA  74.3 
Ss Tg meas (°C) 71.2 67.8 70.0 67.0 68.3 57.5 71.7 68.0 NA  74.2 
Ph Tg meas (°C) 102.3 100.9 103.6 101.4 96.3 84.8 104.8 103.1 NA  106.0 
Ps Tg meas  (°C) 104.8 104.5 109.9 103.4 102.5 91.8 103.7 99.5 NA  110.6 
Hh Tg meas  (°C) 105.3 103.4 109.0 101.7 97.6 92.7 102.0 104.7 NA  NA  
Hs Tg meas  (°C) 103.7 103.7 109.3 104.3 102.6 91.1 103.7 100.0 94.8 110.0 
S Tg pred  (°C) 67.5 67.5 68.8 65.7 67.9 61.1 68.8 71.5 58.5 66.6 
P Tg pred  (°C) 95.4 95.4 96.7 93.6 95.8 89.0 96.7 99.4 86.4 94.5 
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H Tg pred  (°C) 112.5 112.5 113.8 110.7 112.9 106.1 113.8 116.5 103.5 111.6 
 
 
MULTIPLE LINEAR REGRESSION (MLR) MODEL 
The publicly available software R 35 and R studio (version 1.0.143) were used to build the 
multiple linear regression models. The calculated and predicted parameters (see Table 2) were 
used without units as input variables in the model equations. The measured stability (time to 
crystallisation), the output, was used as the log10 value, stability in days + 1 in order to avoid 
zero values. Using the leaps package in R an exhaustive selection of covariates was made with 
one, two and three as a maximum number of covariates; using backwards, forwards, stepwise, 
and sequential replacement. This was done to insure that the simplest, most effective model 
could be made, so that each parameter improves the model more than can be expected by 
chance. To avoid linear dependency of covariates, the selected parameters were tested for 
intercorrelation and further iterations of parameter selection were made if this was found to be 
higher than 0.9. Once three uncorrelated parameters had been selected, these were used to build 
a model that linked the physicochemical properties with the logarithm of the measured stability, 
i.e. time until onset of crystallisation. As this was a relatively limited dataset (in terms of 
statistical analysis) of ten observation per model, the whole dataset was used to build the 
models, rather than a training and test set method. A leave-one-out cross validation (LOOCV) 
was performed on each model to test its predictability and to calculate the mean square error 
(MSE). This process was repeated for each dataset (combination of polymer and processing 
method), resulting in six MLR models. 
 
RESULTS 
Due to limit of detection of XRPD and DSC, PLM was used as the main method of detecting 
onset of crystallisation, while further crystallisation was confirmed using the inherently more 
quantitative XRPD and DSC methods. In many cases, even when an abundance of crystals was 
observed by PLM, no crystallinity could be detected with either XRPD or DSC (Figure 3).  
 
11 
 
 
FIGURE 3 A) 3Sh with clearly visible crystals under polarised light, C) and D) no melting peak is visible under DSC nor any 
peaks in XRPD. B) 6Ss with abundance of crystals visible, again no melting peak by DSC nor peaks indicating crystallinity in 
XRPD, D) and F). 
 
 
STABILITY 
For each API-polymer mixture the HME solid dispersion appeared as a clear glass after 
extrusion, an indication of amorphicity, except 10Hh, which was cloudy. At the start of the 
stability assessment all the clear glass HME formulations and all the spray-dried formulations 
for all APIs were confirmed to be amorphous, while the cloudy 10Hh formulations were 
confirmed to contain crystals. Crystals were defined as bright white or coloured spots under 
polarised light. In each case it was ascertained that spots in the PLM images displayed a 
distinctive pattern that was not due to any physical defects of the surfaces of the examined 
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samples, such as cracks and sharp edges (Figure 4). Even though the onset of crystallisation 
was the main outcome of this study, once a formulation showed signs of crystallinity, during 
the stability study, it was followed up at each time point after onset to confirm that further 
crystallisation had occurred and that the first onset point was not an artefact of measurement.  
 
FIGURE 4. Pieces of HME formulations under polarised light (A, C and E) and non-polarised light (B, D and F). (A) 8Ph 
sharp edges (blue, thin arrows) are visible under polarised light, the visible lines are confirmed as part of the glass rather than 
crystals (B). Panels C and D show visible crystals (orange, thick arrows) under polarised light, 9Hh and 8Sh respectively. No 
sign of crystals can be seen under normal light in D but crystals are clearly observed in F. 
 
At the start of the stability study the spray-dried solid dispersions were dispensed into the 
storage vials as dry dispersible powders but after a period stored at 40 °C / 75% RH most of 
the powders had converted to solid glasses, similar in appearance to the HME glass. In most 
cases signs of crystallisation were not seen until after the transformation of the powder to the 
glass. How fast this transformation was observed depended on both the polymers and the APIs 
as some solid dispersions were more resistant. The first transformation was seen after one 
month at accelerated conditions for 5Ss, 6Ss and 9Ss. Most appeared after two months and a 
few after four months, 3Ps, 7Ps and 10Ps. The only formulation not to show any signs of 
transformation during the one year stability study, of those containing PVP-VA and SOL was 
4Ss. An example of this transformation can be seen in Figure 5 where the first image shows a 
well-dispersed powder; panels C and D shows a piece where signs of merged particles can be 
seen but in the last image no signs of previous particles are observed. This transformation to 
glass was not observed under less accelerated conditions and not for any of the HPMCAS 
spray-dried formulations. 
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FIGURE 5. Panels A, C, and E show solid dispersions under cross-polarised light while panels B, D, and F show the same 
samples imaged under normal light. Panels A and B show a well-dispersed powder, 6Hs, where typical bubble-like particles 
(red, thin arrows) can be observed. Panels C and D show a piece of 6Ps where the powder has transformed into glass. It is 
possible to still see signs of the original particles that have merged (blue, thick arrows). Panels E and F show a large piece of 
6Ss formulation. Here the transformation into glass is more complete than in (D) as no signs of previous particles can be 
observed. Crystallisation can be observed (yellow, curvy arrows) in C and E.  
 
The onset of crystallisation was noted for each formulation. For those solid dispersions where 
no signs of crystals could be found after 6 months at 40 °C / 75 % RH a 1-year time point was 
added. In Figure 6 the stability, i.e. the last time point where no signs of crystals were observed, 
is summarised for each API–polymer combination. For example, if crystals were first observed 
at 4 weeks, crystals must have started growing between time points 1 week and 4 weeks. Thus 
the last data point of confirmed amorphicity is 1 week and that is the noted stability.  
 
An overview of the difference in stability is provided in Figure 6. Significant differences in 
stability between the polymers can be observed for some APIs. As an example, the last 
amorphous time point for felodipine was observed as 1 weeks in the HPMCAS HME 
formulation, at 16 weeks when formulated with PVP-VA by HME and at 24 weeks with SOL 
by HME. A similar example can be found in the spray-dried formulations, probucol was only 
stable for 7 days in PVP-VA, for a moderate 111 days in HPMCAS but was still amorphous at 
the one-year point (379 days) in SOL. Some similarities are also observed between the 
polymers, aprepitant seems to be the least stable of all the drugs by HME regardless of the 
polymer used, although the onset of crystallisation time varies from zero to 16 weeks. 
Additionally, differences were observed between the two methods, spray-dried formulations 
seem to be more stable for PVP-VA and HPMCAS while the opposite is true for SOL 
formulations. 
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FIGURE 6 shows measured stability of the solid dispersions (last time point were no crystals were observed plotted as 
log(Stability).  
 
MLR MODELS 
Six statistical MLR models were constructed, one for each combination of polymer and 
manufacturing method. Even though each modelling process started with the same predicted, 
calculated, or measured parameters, none of the models were identical, each indicating that 
different parameters were influential in the stability of that particular polymer dispersion and 
manufacturing method. This provides a direct indication of why it has been difficult to find 
agreement among different studies on the most important parameters to consider when seeking 
the most stable solid dispersion formulation and production method. 
Due to the relatively limited dataset (although very large compared to previous studies), the 
number of independent physicochemical parameters in each model was limited to three. 
Models containing one and two parameters were also built as well as models containing pooled 
datasets. Additionally, there is a greater risk of overfitting when using small data sets which is 
why leave-one-out validation was used to explore the general features of the data. The first step 
was determining which three parameters had the strongest correlation with the stability of the 
formulations.  
 
 
15 
 
 
Table 3 an overview of the abbreviations used for the different polymer - manufacturing method combinations 
Abbreviation Formulation 
Sh SOL HME 
Ss SOL spray-dried 
Ph PVP-VA HME 
Ps PVP-VA spray-dried 
Hh HPMCAS HME 
Hs HPMCAS spray-dried 
 
Once the three most influential parameters had been chosen, a MLR model was derived using 
the stability of the ten drugs and the parameters. The models, adjusted R2 (R2adj) and mean 
square error are listed in Table 4. The Sh stability model shows a negative correlation with the 
number of H-bond acceptors and the number of chiral atoms, and a positive correlation with 
topological polar surface area. If number of F atoms was included in the model the adjusted R2 
was 0.918 and the MSE was 0.08, the model was then log(stability) = 2.675-0.04 nF – 0.132 
nAliphRing – 0.001 MW. Ss formulation stability is positively correlated with measured glass 
transition temperature (Tg,meas) and molecular polarizability while negatively correlated with 
the number of N atoms in the drug. Stability of Ph shows a positive correlation with predicted 
glass transition temperature (Tg,pred) and a negative correlation with number of H-bond donors 
and the melting point of the API. The nitrogen count and Tg,pred are positively correlated with 
stability of Ps while the number of aromatic atoms shows a negative correlation. The Hh 
stability shows negative correlation with number of HBD and lipophilicity while sulphur count 
is positively correlated. Both ring count and number of rotatable bonds is positively correlated 
with the stability of HPMCAS spray-dried but the number of nitrogen atoms is negatively 
correlated. The optimal models have R2adj values between 0.798 and 0.895.  
The MSE was calculated from a leave-one-out validation of each model. In a leave-one-out 
cross validation (LOOCV) one of the data points (formulations) is excluded from the dataset 
used to build the model. The same procedure is used as with the whole dataset and the 
parameters are selected before the model is built. For example, a model was built leaving out 
the nifedpine data. The new model is then used to predict the stability of the drug that was 
excluded, nifedipine. This is repeated ten times, each time excluding one API and predicting 
the stability of that API. The MSE of these predictions was then calculated and it gives an 
indication of the predictability of the models. The comparison of predicted and measured 
stability from each LOOCV can be seen in Figure 7. Substantial difference in MSE can be seen 
between the models (see both Figure 7 and Table 4), the lowest MSE is in the Sh model, 0.08, 
while the highest is seen in the Hh model, 3.481.  
Models were also made using only one and two parameters (Table 4), these had lower R2adj 
(0.231-0.659) and (0.621-0.781) respectively but in most cases lower MSE (0.029-7.445) and 
(0.068-2.619). Attempts to build models using pooled data were unsuccessful, with R2adj 
ranging from -0.1 to 0.33. These included six pooled dataset, one including all data, one for 
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each method – containing data from all polymers and one for each polymer which included 
both methods. 
TABLE 4. Summary of models, including adjusted R2 and MSE values. The following abbreviations are used, nCov – number 
of covariants, R2adj – adjusted R2, MSE – mean square error, logStab – log Stability, tPSA – topological polar surface area 
atoms, HBA – H, mp – melting point, nF – number of F atoms, nS – number of S atoms, nN – number of N atoms, HBD – 
number of H bond donors, nRot – number of rotatable bonds, molPol – molecular polarizability, Tgpred – predicted  Tg using 
the Gordon-Taylor equation, Tgmeas – measured Tg, nRing – number of rings, nAr – number of aromatic atoms, nHet – number 
of heteroatoms, sp3 – number of sp3 carbon atoms. 
Name nCov Model R2adj MSE 
Sh 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 2.307 + 0.003 𝑡𝑃𝑆𝐴 − 0.055 𝑛𝐶ℎ𝑖𝑟 − 0.082 𝐻𝐵𝐴 0.891 0.08 
Ss 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −3.864 + 0.081 𝑇𝑔,𝑚𝑒𝑎𝑠  − 0.163 𝑛𝑁 + 0.015 𝑚𝑜𝑙𝑃𝑜𝑙  0.895 0.265 
Ph 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −11.2106 − 0.2355 𝐻𝐵𝐷 − 0.0112 𝑚𝑝 + 0.1536 𝑇𝑔,𝑝𝑟𝑒𝑑 0.815 1.021 
Ps 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −5.252 + 0.079 𝑇𝑔,𝑝𝑟𝑒𝑑 + 0.390 𝑛𝑁 − 0.119 𝑛𝐴𝑟 0.798 2.113 
Hh 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 2.472 − 0.849 𝐻𝐵𝐷 − 0.124 𝐶𝑙𝑜𝑔𝑃 + 0.771 𝑛𝑆 0.827 3.481 
Hs 3 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 0.953 + 0.055 𝑛𝑅𝑜𝑡 + 0.331 𝑛𝑅𝑖𝑛𝑔 − 0.216 𝑛𝑁 0.870 0.781 
Sh 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.988 + 0.078 𝑛𝑆 − 0.042 𝑝𝐾𝑎𝑏 0.781 0.068 
Ss 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −1.829 − 0.059 𝑛𝐻𝑒𝑡 + 0.063 𝑇𝑔,𝑚𝑒𝑎𝑠 0.647 0.308 
Ph 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −0.605 − 0.232 𝑛𝐹 + 0.025 𝑇𝑔,𝑚𝑒𝑎𝑠 0.651 1.517 
Ps 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 2.116 − 0.104 𝑛𝐴𝑟 − 0.389 𝑛𝑁 0.621 1.052 
Hh 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.754 − 0.711 𝐻𝐵𝐷 + 0.480 𝑛𝑆 0.688 2.619 
Hs 2 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.415 + 0.060 𝑙𝑜𝑔𝑃 + 0.102 𝑛𝐶ℎ𝑖𝑟 0.700 0.276 
Sh 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 2.033 − 0.042 𝑝𝐾𝑎𝑏 0.659 0.029 
Ss 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = −0.667 + 0.038 𝑇𝑔,𝑚𝑒𝑎𝑠 0.272 0.392 
Ph 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.831 − 0.199 𝑛𝐹 0.605 0.394 
Ps 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 0.839 + 0.012 𝑡𝑃𝑆𝐴 0.231 7.445 
Hh 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.669 − 0.479 𝐻𝐵𝐷 0.534 0.520 
Hs 1 𝑙𝑜𝑔𝑆𝑡𝑎𝑏 = 1.599 + 0.030 𝑠𝑝3 0.483 0.149 
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FIGURE 7 Leave-one-out cross validation of each of the six models. The error bars on the predicted stability is the MSE of 
each model.  
 
A further external validation was performed. A recent study compared the stability of three 
solid dispersion formulations of lapatinib (structure Table 5), namely SOL, PVP-VA and 
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HPMCAS. These were spray-dried at 40% w/w API and stored at 40 °C / 75% RH. It was 
found that the formulation containing HPMCAS was the most stable by far, staying amorphous 
for the six months tested while both PVP-VA and SOL formulations were crystalline by one 
month 36. Using our Ss, Ps and Hs models, the stability of lapatinib formulations was predicted 
in each polymer. The models ranked the stability correctly both using two- and three-parameter 
models. For the three-parameter models the stability was less than one month for SOL and 
PVP-VA and more than six months for HPMCAS, reproducing perfectly the measured stability 
(Table 5) 
Table 5. Measured 36 and predicted stability (using three covariant models) of lapatinib formulations. The 
molecular structure of lapatinib (right). 
 SOL PVP-VA HPMCAS 
Measured < 1 month < 1 month > 6 months 
Predicted 19 days 0 days 220 days 
 
DISCUSSION 
Most studies considering the stability of solid dispersions solely rely on DSC and XRPD for 
detecting crystals, not PLM 7,37–40. However it has been observed in this study that specifically 
at low drug loading these two methods lack the sensitivity to detect onset of crystallinity 
accurately. Here PLM has therefore been used as a primary method of detection as it is known 
to be a sensitive and rapid method to detect small amounts of crystalline material in amorphous 
matrices 41–43.  
 
STABILISING POLYMER 
For some drugs there is a clear difference in stability between polymers while for others there 
is minimal difference. For instance probucol was very stable in both formulations containing 
SOL. No crystals were observed up to six months in HME and it was still amorphous after one 
year in spray-dried formulations. Probucol was the only drug that stayed amorphous in spray-
dried SOL for more than four months and the only formulation to stay amorphous for the whole 
year tested. However for PVP-VA it was one of the first APIs to show signs of crystallisation 
in both methods, 4 and 8 weeks, respectively for spray-dried and HME. In HPMCAS the 
crystallisation onset was determined to be 4 weeks for HME and 24 weeks for spray-dried. 
When considering the physicochemical properties of probucol, ClogP stands out as extreme. 
Probucol has a ClogP of 10, which is the highest of the APIs used in this study. It is possible 
that this attribute is connected with this difference in stability, the PEG and PCL parts of SOL 
may better stabilise this highly lipophilic molecule compared to the more hydrophilic PVP-
VA, and the amphiphilic HPMCAS 44. Other drugs such as fenofibrate started crystallising at 
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the same time for all three polymers, at 8 weeks for HME HPMCAS and PVP-VA and spray-
dried SOL.  
When comparing the stability of spray-dried solid dispersions it is interesting to note that for 
each of the polymers, two APIs had shown signs of crystallisation by two months. However 
out of the six crystallised formulations only two contained the same drug. For HPMCAS it was 
celecoxib and nifedipine; probucol and fenofibrate for PVP-VA; and orlistat and fenofibrate 
for SOL. It can therefore be assumed that this difference is due to the stabilising effect of the 
polymer or a lack thereof. Even the least stable drugs behave quite differently depending on 
the polymers. This would indicate that relative stability is not solely due to the method used or 
the inherent instability of the API, but how well the polymer can influence the physical stability 
of the dispersed drug.  
Using a polymer with a high Tg will increase the Tg of its solid dispersions as the API Tg values 
are generally quite low (here ranging from -45°C to 85°C). Solid dispersions with high Tg 
values are generally thought to be more stable than ones with a lower Tg 
16. Although some 
studies have found a strong correlation between increasing polymer Tg and decreasing 
crystallisation tendency, others have found no such connection or even shown an opposite trend 
28–31. In this study the three polymers used have a wide range of physicochemical properties, 
such as Tg, SOL 70 °C, PVP-VA 103 °C and HPMCAS 120 °C 
45–47. The results show that 
generally SOL is the most stabilising polymer in HME formulations despite having the lowest 
glass transition temperature. The same does not apply to the spray-dried formulations where 
PVP-VA and HPMCAS show better crystallisation inhibition properties. However, PVP-VA 
and HPMCAS were spray-dried at a temperature below their Tg while for SOL this was above 
its Tg. Whether this affected stability is unclear. It is clear, however, that there are more factors 
that contribute to stability than just the polymer or solid dispersion Tg. 
STABILISING INTERACTIONS 
Generally there are four different types of specific interactions that can occur between an API 
and a polymer, in order of decreasing bond strengths: ionic bonds > hydrogen bonds > dipole–
dipole interactions > van der Waals interactions. Ionic bonds are strong attractions between 
two oppositely charged molecules. A hydrogen bond (H-bond) is an electrostatic interaction 
between a hydrogen and an electronegative atom (O, N or F), these can occur both between 
two identical molecules (API-API) and different molecules (polymer-API). A dipole-dipole 
interaction can occur between two polar molecules, when they line up so that the positive part 
of one molecule is opposite the negative one of the other molecule. The weakest of the 
interactions is the van der Waals interactions, which are induced dipolar interactions that can 
occur between any functional groups. Specific interactions between drug and polymer can 
impact the physical stability of solid dispersions. For instance H-bonds between polymer and 
drug can hinder crystallisation by reducing the amount of drug in the conformation needed for 
crystallisation. H-bonding can also occur between APIs, which can facilitate crystallisation. 
However, if there are more or stronger H-bonds available between API and polymer, or 
amorphous API-API than between crystalline API-API this can impede crystallisation 16,44,48.  
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In a study of solid dispersions containing vitamin C and several polymers the influence of H-
bonding between polymer and drug on physical stability was considered. As well as H-bonding, 
the effect of polymer hygroscopicity and Tg were examined. It was found that the formation of 
strong H-bonds between the polymer and drug in dispersions was the most important factor 
inhibiting crystallisation of vitamin C. The hygroscopicity of the polymer played some part in 
stability, especially when the solid dispersions were stored at a high RH. No correlation could 
be found between polymer Tg and physical stability of solid dispersions 
28. In a similar study 
performed by Van den Mooter et al. it was observed that in absence of any polymer-drug 
interaction, polymer Tg was an important stabilising factor 
30.  
Functional groups that can act as H-bond acceptors or donors are present in all three polymers. 
H-bond donors include alcohol and carboxylic acid both present in HPMCAS. Amide (PVP-
VA, SOL), esters (SOL, PVP-VA and HPMCAS) and ethers (HPMCAS, SOL) can all act as 
H-bond acceptors 42. Thus only HPMCAS has H-bond donors while all polymers have H-bond 
acceptors present. In Table 2 the number of H-bond donors and acceptors are listed for each of 
the drugs. It can be observed that these numbers vary greatly between the different drugs, H-
bond acceptors range from two to nine while H-bond donors range from zero to four. If the 
stability of solid dispersions was mostly dependent on the ability of the drug and polymer to 
make specific bonds such as H-bonds it would be expected that the drugs with large number of 
H-bond acceptors would be more stable in HPMCAS than PVP-VA and SOL while drugs with 
no H-bond donors would not be sufficiently stabilised by PVP-VA and SOL as no interaction 
could be made. Itraconazole, which has the greatest number of H-bond acceptors, first showed 
signs of crystallisation at 16 and 24 weeks, respectively for HME and spray-dried HPMCAS 
solid dispersions. However, both aprepitant and ritonavir were very unstable in HME 
HPMCAS but both have six H-bond acceptors. Fenofibrate, which has no H-bond donors, was 
the least stable spray-dried formulations for both SOL and PVP-VA but the HME SOL was 
stable through the whole six months of testing. It is therefore clear that there are further 
properties that contribute to the stability than just the ability of drug and polymer to interact, 
even though that is a probably important factor. 
 
Water, once absorbed into the formulation, can disrupt any H-bonding between the drug and 
polymer. Furthermore water can act as a plasticizing agent and increase molecular mobility 
49,50. Thus even if a solid dispersion formulation started out stable with abundance of stabilising 
H-bonds, at accelerated conditions these might be removed by water and thus cause instability 
and crystallisation. In most cases for SOL and PVP-VA, crystallisation was not observed while 
the spray-dried formulations were still a dispersible powder but only once they had transformed 
into a solid glass, which indicates the presence of water. PVP-VA is a very hydrophilic polymer 
and thus quite hygroscopic, absorbing 10% water at 50% RH. Relative to PVP-VA, HPMCAS 
and SOL are less hygroscopic, taking up 6-7% water at 75% RH and 10 % water at 70 % RH, 
respectively 51. The effect differences in hygroscopy have on the stability of the formulations 
can be seen clearly in the case of the spray-dried formulations above. Especially when 
comparing formulations with PVP-VA and HPMCAS. PVP-VA spray-dried formulations form 
a glass after a while when exposed to very high humidity, 75% RH. The powder seems to melt 
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and/or dissolve into a glass and simultaneously crystals start forming. This transformation of 
powder into glass did not occur for the HPMCAS spray-dried formulations, even after one year 
at high humidity. It was deduced that this transformation was mainly due to the hygroscopy of 
the PVP-VA and SOL polymer, as it was not seen at less humid conditions (data not shown). 
As water negatively affects the stability of the dispersion, this transformation can be regarded 
as a step towards crystallisation. Despite the transformation of spray-dried formulations due to 
uptake of water for PVP-VA formulations they were still overall, more stable than the 
corresponding HME formulations.  
 
PROCESSING METHOD 
Janssens and coworkers studied the influence of processing method on the stability of an 
itraconazole – Eudragit (acrylic polymers often used in solid dispersion formulations) solid 
dispersion 52. Comparing solid dispersions produced with three different methods, spray-
drying, film-casting, and hot melt extrusion. The maximum drug loading that could be 
stabilised by Eudragit was 27.5% for spray-drying and 15% for each of the other two methods. 
This shows that the processing method can have significant effects on the stabilisation of solid 
dispersions 52.  
A comparison of HME and spray-drying in regard to interaction, drug distribution and 
homogeneity indicated a lower achievable drug loading by HME than spray-drying. However, 
HME formulations were more homogenous, stable and showed stronger interactions than the 
spray-dried examples 53,54.  
Some effects on stability are due to the processing method. In some cases a reason might be 
quite clear, such as aprepitant being the least stable drug in HME formulations. Aprepitant has 
a very high melting point, 255 °C and was extruded at a low temperature (160°C). Other effects 
of the processing method are not as clear. Only in four cases was the time of crystallisation 
onset the same for the two methods in two similar formulations, these are SOL-itraconazole, 
SOL-estradiol, PVP-VA -itraconazole and PVP-VA – felodipine. In all other cases the onset 
of crystallisation time was differed between the two methods. The largest difference was 
observed for SOL-fenofibrate, where the spray-dried formulation showed signs of crystals after 
eight weeks while no crystals were observed in the HME until after one year.  
When comparing the two processing methods it can be observed that overall, for SOL, HME 
seems to produce more stable solid dispersions than spray-dried, while the opposite appears to 
be the case for both PVP-VA, and HPMCAS. This indicates that the processing method has a 
profound effect on the solid dispersions stability. It is unlikely that specific bonds would only 
be present using one method not the other, therefore relative stability must be directly linked 
with attributes of the methods. These might include, for example, residual solvents that can 
destabilise the solid dispersion, in case of spray-dried formulations. Different compounds can 
retain varying amounts of solvent which might in some cases be responsible for the observed 
difference in stability. 
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MLR MODELS 
All six models (Table 4) contain three physicochemical parameters, but no two models contain 
the same three, showing the complexity of the stability of solid dispersions. However some 
general rules can be deducted from the six models. The following are correlated with increased 
stability of the solid dispersion. 
1. Increased Tg of the dispersion (measured or predicted)  
2. Increased molecular flexibility of the API 
3. Decreased number of H-bond donors (or Fluorine / Nitrogen atoms) 
The first rule is in good agreement with previous studies. As stated above many studies have 
considered the correlation between Tg and solid dispersion stability 
55. This often relates to 
choosing a high Tg polymer in order to obtain a solid dispersion with a high Tg. Moreover, 
storing the solid dispersion 50°C below the Tg of the solid dispersion reduces the molecular 
mobility to a minimum, thus increasing the stability (reviewed in 56). Thus, for storing the solid 
dispersion at 40°C, a solid dispersion with at least a Tg of 90 °C would be preferable. Here, 60 
% of the solid dispersions tested had a Tg at least 50 °C above the storage temperature. 
The second rule indicates that the more flexible API molecules are, the less likely they are to 
adopt the correct conformation for crystallisation. In the models the parameters relating to 
flexibility are aromatic atom count, rotatable bonds, chiral atoms and ring count. The 
parameters hindering flexibility, aromatic atom count and chiral atoms, were negatively 
correlated with stability while the opposite was observed for rotatable bonds, which increases 
flexibility. Ring count was positively correlated although it would be expected to be negative, 
however, this parameter only occurred in the model with the lowest R2adj. Aromatic rings can 
interact strongly through van der Waals interactions and π-π stacking, symmetry drives 
interactions and intermolecular bonding, while ring structures have been showed to cause dense 
packing structure in crystals, all of which can drive crystallisation 18. 
A predictive model using a partial least squares projection to latent structure discriminant 
analysis (PLS DA) was built based on experimentally determined glass forming ability of 16 
drugs. The model showed a negative correlation between glass forming ability and number of 
benzene rings, but a positive correlation to branching of the carbon skeleton, molecular 
symmetry and distribution of electronegative atoms in the API 57. Another study found that 
APIs with high molecular weight and flexible structures were more likely to be glass formers 
than small rigid molecules 58. Several models using calculated, predicted and measured 
parameters have been built to predict the amorphous stability of APIs. In models containing 
rotatable bonds these were positively correlated with stability whilst aliphatic rings were 
negatively correlated 23. These studies only examined the API alone and not in a solid 
dispersion as here, moreover two of them only look at glass-forming ability, not stability. 
However, they show that flexibility and structural complexity of the API is strongly connected 
with its crystallisation tendency, which was highlighted by four flexibility/complexity (nChir) 
parameters in the models above. It can therefore be concluded that in regards to flexibility of 
the API, the same applies to glass forming ability of API on its own and the stability of the 
amorphous form in a solid dispersion.  
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The first two rules are intuitively expected whereas the third one is less so. H-bonds are an 
important factor to stabilise solid dispersion as discussed before. Several studies have found 
hydrogen bonding to be important for the glass forming ability or stability of glasses 22,23,59. 
Furthermore, a positive correlation was found between well-distributed electronegative atoms 
and glass forming ability, which may be due to the H-bonding ability of such atoms 18,57. The 
atomic mass-weighted third-order R autocorrelation index (R3m) molecular descriptor has 
been found to be the most significant predictor of miscibility in PVP-VA solid dispersion. This 
was based on experimental data from 12 APIs. The R3m is associated with electronegative 
atoms and their positions in the molecule 60. None of these studies considered the stability of 
solid dispersions in the context of H-bonding. Here, however, H-bond donors and acceptors, 
as well as number of nitrogen atoms are shown to be negatively correlated with stability, in all 
cases but for N count in the Ps model. For the three polymers studied here only HPMCAS has 
any H-bond donors, but all have H-bond acceptors. However, even if there are H-bond 
acceptors available in the carrier polymer that does not necessarily mean that API-polymer H-
bonds will actually be formed. Instead these H-bond donors/acceptors in the APIs could lead 
to API-API bonding or API-water H-bonding, both of which lead to decreased stability and 
more rapid crystallisation.  
Our proposed rules are not intended to be absolute but to suggest guidelines, and, due to the 
complexity of these systems, exceptions must be expected. E.g., even though increased Tg is 
correlated with increased stability of SOL HME, solid dispersions were the most stable of the 
HME formulations overall, despite SOL having the lowest Tg out of the three polymers. Similar 
examples can be found for the flexibility. If the two extremes are compared, estradiol is the 
most rigid API in the study with three aliphatic rings, one aromatic ring and no rotatable bonds. 
Orlistat is the other extreme with only one aliphatic ring, no aromatic rings and 23 rotatable 
bonds. If solid dispersion stability was only dependent on API flexibility orlistat would be 
expected to be much more stable than estradiol in all formulations. However, this is not the 
case, orlistat is more stable in two formulations PVP-VA spray-dried (52weeks vs 26 weeks) 
and HPMCAS HME (4 weeks vs 1 week). In two instances the stability is the same for the two 
drugs in comparable formulations: SOL HME and HPMCAS spray-dried, while in the latter 
two formulations estradiol is more stable than orlistat.  
The MSE ranges from minimal in Sh model to very large in the PVP-VA models in particular. 
If the predicted values are compared to the measured ones they are overall mostly in good 
agreement. However, especially for the PVP-VA and Hh models there are a few APIs that are 
very poorly predicted, such as ritonavir in both Ph and Hh or fenofibrate in Ps. These, during 
the LOOCV process, were predicted using models that varied from the main models. The 
LOOCV models for these drugs used parameters for which the APIs had extreme values, 
differing greatly from the rest, such as for ritonavir both Ph and Hh models contained tPSA 
which in both cases ritonavir has the highest value by far or 145 compared to most other well 
under 100. This difference in chosen models in LOOCV is mostly due to the relatively small 
dataset, with more data the models are more robust and less likely to be as affected by leaving 
out a single value.  
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The purpose of these models is to indicate which combination of processing method and 
polymer carrier is most likely to give a stable solid dispersion. Thus the models are used to 
rank the stability of the formulations so that the best combination can be found. Figure 8 shows 
the ranking of formulation combinations.  
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FIGURE 8 Ranking of formulation combinations each API and polymer-manufacturing combination. The error bars show the 
MSE of each model. The predicted ranking is in good agreement with the measured stability. The following abbreviations are 
used: SH – SOL HME, SS – SOL spray-dried, PH – PVP-VA HME, PS – PVP-VA spray-dried, HH – HPMCAS HME and 
HS – HPMCAS spray-dried. 
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When comparing the models using one, two and three covariates the following can be observed, 
as expected the R2adj falls when number of covariates is decreased. However when looking at 
the MSE this decreases in four cases out of six. The lower MSE might suggest that the higher 
number of covariates is over-fitting the model. In order to test the models against over-fitting 
an external validation is needed. 
The external validation shows that the models are nevertheless able to correctly predict the 
ranking of formulations containing a novel drug. Moreover the predicted stability was in very 
good agreement with the measured stability, thus showing that despite a relatively small 
dataset, in terms of statistics, the models can be applied on real data to give a true ranking of 
formulations, which is promising as a support tool in solid dispersion formulation development.  
CONCLUSIONS 
60 solid dispersions were produced successfully using ten APIs, three polymers and two 
processing methods. An accelerated stability study has shown significant difference in time to 
crystallisation dependent on both choice of polymers and processing method. This extensive 
experimental dataset provides new insights into the complexity of the stability of solid 
dispersion systems. There are, as previously described, many factors that influence their 
stability. However, there are some conclusions that can be drawn, such as HPMCAS and PVP-
VA are more likely to give a stable formulation using spray-drying, while HME seems to be 
more favourable for SOL solid dispersion formulations.  
Six predictive statistical models were built, which show the potential of using such models in 
formulation development. Furthermore, none of the models are identical which indicates the 
complexity of these systems. Three rules that could guide formulation development can be 
deduced. Increased stability is correlated with increased Tg of solid dispersion, as are decreased 
number of H-bond donors and increased molecular flexibility of the API. The LOOCV showed 
good predictability which was confirmed in an external validation of three formulations.  
Future studies are planned to add data to the models to further increase their robustness and 
possibly to use as an external validation set.  
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